TheraRadar
← Back
Data updated: Jun 28, 2026

LINDE GAS PUERTO RICO INC

Pharma
Pharmaceuticals

LINDE GAS PUERTO RICO INC is a pharmaceutical company with 3 FDA-approved products.

2013
Since
3
Drugs
-
Trials
2
New Drugs (2yr)
Modality:
3 Small Molecules

LINDE GAS PUERTO RICO INC's Key Drugs

LINDE GAS PUERTO RICO INC's core commercial portfolio centers on OXYGEN, USP, NITROGEN, NF, MEDICAL AIR, USP — its most strategically important drugs approved in the last 15 years.

OXYGEN, USP
Respiratory
Approved 2013
NITROGEN, NF
Other
Approved 2013
MEDICAL AIR, USP
Respiratory
Approved 2013

LINDE GAS PUERTO RICO INC's Recent FDA Approvals

LINDE GAS PUERTO RICO INC secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

MEDICAL AIR, USP NDA
2026-02-17
MEDICAL AIR, USP NDA
2024-07-13
medical air

LINDE GAS PUERTO RICO INC's Therapeutic Areas

Disease areas where LINDE GAS PUERTO RICO INC has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

LINDE GAS PUERTO RICO INC Pipeline Snapshot

Active clinical trials for LINDE GAS PUERTO RICO INC across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • OXYGEN, USP leads revenue
  • • 3 key drugs tracked

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling